Bio-Techne reported $1.22B of revenue over the trailing twelve months, −0.38% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.22B (to Q4 2026). Net income: $110M, trailing twelve months to Q3 2026. Free cash flow: $263M, trailing twelve months to Q4 2026. Operating margin: 21%, trailing twelve months to Q4 2026.

TECHBio-Techne

Healthcare

$72.47+37% 1Y

$72.47

$43.2252 weeks$72.62

TECH as reported

Bio-Techne reported $1.22B of revenue over the trailing twelve months, −0.38% on the year before. 11 reported series are charted on this page, each one as filed.

$1.22B

Revenue, trailing twelve months · to Q4 2026 · −0.38% against the twelve months before

Net income: $110M
Net income · trailing twelve months to Q3 2026
Free cash flow: $263M
Free cash flow · +2.6% year on year · trailing twelve months to Q4 2026
Operating margin: 21%
Operating margin · trailing twelve months to Q4 2026

Details›

Every series Ryufin has for TECH, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.22B	−0.38%	Q4 2026
Net income	$110M	n/a	Q3 2026
EPS	$1.15	+150%	Q4 2026
Gross margin	66%	n/a	Q4 2026
Operating margin	21%	n/a	Q4 2026
Net margin	9.2%	n/a	Q3 2026
ROE	4.3%	n/a	Q3 2026
ROA	3.4%	n/a	Q3 2026
ROIC	6.0%	n/a	Q4 2026
Free cash flow	$263M	+2.6%	Q4 2026
P/E	63.0	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.